We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Final Guidance on Expedited Drug Programs Details New Flexibility in Manufacturing and Quality Data
Final Guidance on Expedited Drug Programs Details New Flexibility in Manufacturing and Quality Data
The FDA can exercise flexibility on the quality manufacturing information it requires drugmakers to present under expedited drug approval processes, says a final guidance.